DNA-encoded library and AI-driven small molecule drug discovery partner
X-Chem combines DNA-encoded chemical libraries, discovery chemistry and its ArtemisAI software to find small molecule hits for drug developers. The stack pairs RDKit cheminformatics with Java, Python, React and an AWS container footprint (EKS, ECS, Lambda) still running alongside VMware and Hyper-V. Job posts point to folding legacy products into a cloud-native platform and moving ML models into production.
X-Chem is a privately held drug discovery company headquartered in Waltham, MA, founded in 2010 and employing 201–500 people. It serves pharmaceutical and biotech companies working on difficult therapeutic targets. Its work spans the early discovery stages, from screening and hit identification through lead optimization and candidate selection. Partners can engage through integrated project support, screening and follow-up services, or licensed access to the ArtemisAI software platform. Current hiring extends to Canada and Hungary.
X-Chem uses Java, Python, C#, React and RDKit, runs on AWS (EKS, ECS, Lambda) with Docker and Kubernetes, and relies on PostgreSQL, MongoDB, Oracle, NetSuite, Salesforce, SuccessFactors, Power BI and Tableau.
X-Chem is integrating legacy products into a unified cloud-native platform, modernizing legacy components, putting machine learning models into production, and expanding discovery collaborations from hit finding to candidate generation.
X-Chem, headquartered in Waltham, MA, is currently hiring in Canada and Hungary, with openings across HR, partnerships and engineering.
Other companies in the same industry, closest in size
X-Chem, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.